Abstract
Background Japan started vaccinations for COVID-19 in late February, 2021, mainly using BNT162b2 mRNA COVID-19 vaccine. At that time, N501Y strain was emerging. Later, L452R strain appeared in Japan.
Object We evaluated effects of COVID-19 vaccination and variant strains on infectiousness in Japan.
Method The effective reproduction number R(t) was regressed on vaccine coverage and the shares of variant strains along with data of temperature, humidity, mobility, and countermeasures. We presumed two definitions for vaccine coverage: at least a single dose with a 12-day delay and a second dose. The study period was February, 2020 through July 18, as of August 10, 2021.
Results Estimation results indicate that vaccine coverage for both first and second doses wast significant, but positive. Moreover, infectiousness of the mutated strain N501Y decreased significantly, but that of L452R was not significant.
Discussion and Conclusion Estimation result for vaccine coverage implies that vaccine did not reduced infectiousness at all. Also, mutated strain with higher infectiousness were not confirmed. Close and continuous monitoring is necessary.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All information used for this study has been published. There is therefore no ethical issue related to this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
I extended the data for about one month.
Data Availability
Japan Ministry of Health, Labour and Welfare. Press Releases.(in Japanese)
